Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
Kowloon, HK
Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.05% | +7.14% | +1.19% | +19.16% | +17.51% | +16.97% | +19.16% | +50.00% | +99.22% | +51.79% | +86.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.4% Q4'25: -5.1% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+6.1% Q4'25: +19.9% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+35.5% Q4'25: +0.0% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+29.5% ★ Q4'25: +19.8% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+19.9% ★ Q4'25: +12.3% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q4'25: 0.00× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-12 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-11 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-07 | A+ | 5/5 | 3/5 | 4/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-06 | A+ | 5/5 | 3/5 | 4/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-05 | A+ | 5/5 | 3/5 | 4/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-04-30 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-24 | A+ | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Zhang | Executive Chairman, Chief Executive Officer & Compliance Officer | 931.4K | male |
| Xiao Guang Zhang | GM & Executive Director | 552.4K | male |
| Bao Gang Zhao | Chief Financial Officer & Executive Director | 494.6K | male |
| Yi Zhang | Executive GM & Executive Director | 444.9K | male |
| Guo Wen Wu | Deputy Sales Director & Executive Director | 368.6K | male |
| Xiang Fu Xu | Deputy Technical GM & Executive Director | 245.0K | male |
| Sai Cheong Mok ACCA FCCA | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8049.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
